Inventor · disambiguated record
Rik Rademaker
Also filed as: RADEMAKER RIK
28 granted patents·18 pending applications·191 citations·filing 2015–2025
97Inventor score
Top patents by PatentIndex Score
46 records- 0198US11542323B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Jan 3, 2023·6 cites·24 claims
- 0298US11524995B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Dec 13, 2022·6 cites·20 claims
- 0398US11440966B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 13, 2022·12 cites·21 claims
- 0498US11084882B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2020·Granted Aug 10, 2021·8 cites·11 claims
- 0597US11421024B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Aug 23, 2022·6 cites·23 claims
- 0697US10800836B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2016·Granted Oct 13, 2020·10 cites·10 claims
- 0797US10647764B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 0897US10647763B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 0997US10640554B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 5, 2020·9 cites·14 claims
- 1096US11091557B2Methods of producing multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2017·Granted Aug 17, 2021·10 cites·20 claims
- 1196US10364285B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 30, 2019·13 cites·9 claims
- 1296US10358484B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 1396US10358483B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 1495US12077596B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 3, 2024·2 cites·20 claims
- 1595US11939388B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Mar 26, 2024·2 cites·13 claims
- 1695US10358482B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·11 cites·9 claims
- 1794US10407501B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2015·Granted Sep 10, 2019·15 cites·19 claims
- 1893US10544220B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2016·Granted Jan 28, 2020·18 cites·12 claims
- 1992US11613575B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2019·Granted Mar 28, 2023·4 cites·18 claims
- 2092US11359015B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2016·Granted Jun 14, 2022·6 cites·24 claims
- 2191US11008399B2AntibodiesGENMAB AS·Filed 2020·Granted May 18, 2021·2 cites·22 claims
- 2290US10882913B2Anti-DR5 antibodies and methods of use thereofGENMAB BV·Filed 2019·Granted Jan 5, 2021·4 cites·23 claims
- 2388US11130819B2AntibodiesGENMAB AS·Filed 2021·Granted Sep 28, 2021·1 cites·30 claims
- 2486US11459395B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2021·Granted Oct 4, 2022·1 cites·19 claims
- 2585US2024392032A1AntibodiesGENMAB AS·Filed 2024·Application pending·0 cites
- 2685US2023312693A1Agents, Uses and Methods for the Treatment of SynucleinopathyH LUNDBECK AS·Filed 2022·Application pending·0 cites
- 2783US2023374131A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2023·Application pending·0 cites
- 2882US10968280B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2020·Granted Apr 6, 2021·1 cites·12 claims
- 2982US2023089969A1Multispecific antibodies against cd40 and cd137GENMAB AS·Filed 2022·Application pending·0 cites
- 3077US2023027394A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 3177US2023087745A1Binding agents binding to pd-l1 and cd137 and use thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 3277US2022389101A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 3377US2022380464A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 3476US11970544B2AntibodiesGENMAB AS·Filed 2021·Granted Apr 30, 2024·0 cites·31 claims
- 3574US2024317861A1Antibodies against pd-l1GENMAB AS·Filed 2023·Application pending·0 cites
- 3673US12247080B2Anti-DR5 antibodies and methods of use thereofGENMAB BV·Filed 2020·Granted Mar 11, 2025·0 cites·15 claims
- 3773US11261254B1AntibodiesGENMAB AS·Filed 2021·Granted Mar 1, 2022·0 cites·30 claims
- 3871US2022324980A1AntibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 3971US2025340647A1AntibodiesGENMAB AS·Filed 2025·Application pending·0 cites
- 4068US2020277397A1AntibodiesGENMAB AS·Filed 2020·Application pending·0 cites
- 4167US2021292418A1AntibodiesGENMAB AS·Filed 2021·Application pending·0 cites
- 4261US2019144554A1Anti-dr5 antibodies and methods of use thereofGENMAB BV·Filed 2016·Application pending·0 cites
- 4359US2020199231A1Bispecific antibodies against cd3 and cd20GENMAB AS·Filed 2019·Application pending·0 cites
- 4453US2020239579A1Antibodies against pd-l1GENMAB AS·Filed 2018·Application pending·0 cites
- 4550US2021369842A1Antibody formulationGENMAB AS·Filed 2019·Application pending·0 cites
- 4650US2023257479A1Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancerGENMAB AS·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Rik Rademaker files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →